Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial.

Michela Del PreteFrançois-Alexandre ButeauFrédéric ArsenaultNassim SaighiLouis-Olivier BouchardAlexis BeaulieuJean-Mathieu Beauregard

Published in: European journal of nuclear medicine and molecular imaging (2018)

Personalized PRRT makes it possible to safely increase tumour irradiation in the majority of patients. Our first results indicate a favourable tolerance profile, which appears similar to that of the empiric regime. The response rates are promising, in particular in patients with NET of pancreatic origin.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
clinical trial
study protocol
peritoneal dialysis
prognostic factors
randomized controlled trial
stem cells
phase ii
phase iii
patient reported outcomes
bone marrow
mesenchymal stem cells
cell therapy